GNLX
GENELUX Corp
NASDAQ · Healthcare · Biotechnology · US
$1.89
−1.46%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.95
From 52W high−76.67%
Volume125411.00
Market cap$85.60M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.95
From 52W high
−76.67%
Volume
125411.00
Market cap
$85.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
37.3
MomentumView details →
1D Return
−1.46%
YTD Return
−55.05%
SummaryUpdated Jun 1, 2026
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Westlake Village, California. The company went public in January 2023 and specializes in developing innovative oncolytic viral immunotherapies designed to treat aggressive and difficult-to-treat solid tumors. Genelux represents a new frontier in cancer treatment, utilizing genetically modified viruses that can selectively target and destroy cancer cells while potentially stimulating the patient's immune system to fight the disease.
Similar companies
Latest newsMore news →